)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
RenovoRx (RNXT) investor relations material
RenovoRx IAccess Alpha Virtual Best Ideas Fall Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.IAccess Alpha Virtual Best Ideas Fall Conference 2025 summary16 Sep, 2025
Commercial progress and market opportunity
Initiated commercialization of FDA-cleared RenovoCath device, exceeding revenue expectations in the first half of the year without a sales force.
13 cancer centers approved to purchase, with four centers repeat purchasing and over 20 additional customers in the pipeline.
Targeting a $400 million initial U.S. market opportunity, with device pricing analogs between $6,000 and $8,500 per unit and multiple treatments per patient.
Lean sales approach with a small team, aiming to cover high-volume academic centers and drive significant revenue growth by 2026.
Gross margins already above mid-60%, expected to improve as manufacturing scales.
Clinical development and technology
RenovoCath enables targeted drug delivery to hypovascular tumors, overcoming chemo-resistance by saturating tumor tissue with high drug concentrations.
Animal and human studies show 100x higher local drug concentration and 50% lower systemic exposure, reducing toxicity.
Outpatient procedure with conscious sedation, short duration, and rapid patient recovery; easy for physicians to adopt.
Patent portfolio includes 19 issued patents worldwide, with ongoing filings to protect new mechanisms.
Potential pipeline expansion into other cancers such as cholangiocarcinoma and non-small cell lung cancer.
TIGeR-PaC phase III trial and clinical results
TIGeR-PaC phase III trial for locally advanced pancreatic cancer nearing enrollment completion, with final analysis expected in late 2026.
Interim analysis showed a six-month survival benefit (21.5 vs. 15.5 months) and a 65% reduction in adverse events compared to standard care.
Positive feedback from the data monitoring committee, with trial continuation recommended.
Additional data on pharmacokinetics to be published in coming quarters; 16 trial centers could transition to commercial customers.
PANTHER post-market registry launched to collect real-world data and support pipeline expansion.
Key metrics for RenovoCath commercial traction?
TAMP's dual benefit: survival and reduced toxicity?
Future strategic options: standalone or partner?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next RenovoRx earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
RenovoRx Inc is a U.S.-based medical technology company focused on targeted drug delivery systems. It develops catheter-based platforms for the localized administration of chemotherapy and other therapeutics, primarily for treating cancers. The company aims to improve patient outcomes by reducing systemic exposure and enhancing precision in treatment delivery. It is headquartered in Los Altos, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage